43 results on '"La Flamme, Anne Camille"'
Search Results
2. Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis
3. Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune‐driven demyelination.
4. Glatiramer acetate treatment normalized the monocyte activation profile in MS patients to that of healthy controls
5. Proteomic changes at 8 weeks after infection are associated with chronic liver pathology in experimental schistosomiasis
6. Expansion and preferential activation of the CD14+ CD16+ monocyte subset during multiple sclerosis
7. Microtubule-stabilizing agents delay the onset of EAE through inhibition of migration
8. Critical role of preproenkephalin in experimental autoimmune encephalomyelitis
9. A joint spotlight on research into the microbial immunity: beyond mere correlations
10. Immunological partners: the gut microbiome in homeostasis and disease
11. Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase 1, randomized, blinded, placebo-controlled trial
12. Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro
13. Type II-activated macrophages suppress the development of experimental autoimmune encephalomyelitis
14. Clozapine administration enhanced functional recovery after cuprizone demyelination
15. Innate IFN-γ ameliorates experimental autoimmune encephalomyelitis and promotes myeloid expansion and PDL-1 expression
16. Comparing methods for ex vivo characterization of human monocyte phenotypes and in vitro responses
17. Amelioration of experimental autoimmune encephalomyelitis by clozapine is not associated with defective CD4 T cell responses
18. Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis
19. Glatiramer acetate treatment normalized the monocyte activation profile in MS patients to that of healthy controls
20. Type II Activation of Macrophages and Microglia by Immune Complexes Enhances Th17 Biasing in an IL-6-Independent Manner
21. Treatment with the Antipsychotic Agent, Risperidone, Reduces Disease Severity in Experimental Autoimmune Encephalomyelitis
22. Expansion and preferential activation of the CD14 + CD16 + monocyte subset during multiple sclerosis
23. Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis
24. Microtubule‐stabilizing agents delay the onset of EAE through inhibition of migration
25. Type II-Activated Murine Macrophages Produce IL-4
26. Proteomic changes at 8weeks after infection are associated with chronic liver pathology in experimental schistosomiasis
27. Remote ischaemic preconditioning does not alter perioperative cytokine production in high-risk cardiac surgery
28. Identification of Cytokeratin 18 as a Biomarker of Mouse and Human Hepatosplenic Schistosomiasis
29. Toll-like receptor responses in tuatara
30. Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro
31. Type II‐activated macrophages suppress the development of experimental autoimmune encephalomyelitis
32. Differential Liver Protein Expression during Schistosomiasis
33. Schistosomiasis protects against multiple sclerosis
34. Schistosomiasis Decreases Central Nervous System Inflammation and Alters the Progression of Experimental Autoimmune Encephalomyelitis
35. Lack of C3 Affects Th2 Response Development and the Sequelae of Chemotherapy in Schistosomiasis
36. Schistosomiasis delays lesion resolution during Leishmania major infection by impairing parasite killing by macrophages
37. Role of Gamma Interferon in the Pathogenesis of Severe Schistosomiasis in Interleukin-4-Deficient Mice
38. IL-4 Plays a Crucial Role in Regulating Oxidative Damage in the Liver During Schistosomiasis
39. Role of IL-6 in Directing the Initial Immune Response to Schistosome Eggs
40. Expansion and preferential activation of the CD14+CD16+ monocyte subset during multiple sclerosis.
41. The Absence of IL-6 Does Not Affect Th2 Cell Development In Vivo, But Does Lead to Impaired Proliferation, IL-2 Receptor Expression, and B Cell Responses
42. Expansion and preferential activation of the CD14(+)CD16(+) monocyte subset during multiple sclerosis.
43. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.